NEW YORK (GenomeWeb) – Biodesix announced today that it has chosen Progenetics to market and distribute its liquid biopsy tests in Israel.

Under the terms of the agreement, Tel Aviv-based Progenetics will market and distribute Biodesix's GeneStrat and VeriStrat tests, which are available for clinical use in patients with non-small cell lung cancer (NSCLS).

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.